| Annual · values | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Operating Cash Flow | -12.28 M USD | -8.30 M USD | -6.65 M USD | -1.85 M USD |
| Depreciation & Amortization | 12000 USD | 183000 USD | 81000 USD | 0 USD |
| Stock-Based Compensation | 529000 USD | 1.63 M USD | 618000 USD | 0 USD |
| Capital Expenditures | 10000 USD | 14000 USD | 19000 USD | 0 USD |
| Cash Flow from Investing | -10000 USD | -14000 USD | -19000 USD | 0 USD |
| Cash Flow from Financing | 10.16 M USD | 8.80 M USD | 14.41 M USD | 675000 USD |
| Dividends Paid | — | — | — | — |
| Stock Buybacks | — | — | — | — |
| Free Cash Flow | -12.29 M USD | -8.31 M USD | -6.67 M USD | -1.85 M USD |
Autonomix Medical Inc. is a medical device company developing precision nerve-targeted therapies to treat diseases involving the peripheral nervous system. Its first-in-class platform technology features a proprietary catheter-based microchip sensing array that detects and differentiates neural signals with ultra-high sensitivity and on-site data processing, surpassing existing technologies. This enables real-time identification of target nerves, followed by proprietary radio frequency ablation to precisely disable them, and verification of treatment efficacy in a minimally invasive transvascular procedure. Initially focused on pain management for pancreatic cancer patients, the platform addresses unmet needs in chronic pain by offering targeted denervation as an alternative to opioids or invasive methods. With potential applications across cardiology, hypertension, pulmonology, gastroenterology, and interventional pain management, Autonomix Medical Inc. equips physicians with innovative tools for accurate diagnosis and therapy. Headquartered in The Woodlands, Texas, the company advances this breakthrough system protected by a global intellectual property portfolio.